I am interested in studying the effects of the inflammatory microenvironment on disease progression and resistance to treatment in haematological malignancies with emphasis on survival and mechanisms of treatment resistance in chronic lymphocytic leukaemia and B cell lymphoma.
CD126 and targeted therapy with Tocilizumab in Chronic Lymphocytic Leukemia. Clin Cancer Res (2016) 15;22(10):2462-9. PMID: 26712690
Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma. Oncotarget (2015) 29;6(29):27816-31. PMID: 26315113
Dysregulation of autophagy in human follicular lymphoma is independent of overexpression of BCL-2. Oncotarget (2014) 5(22):11653-68. PMID: 25362242
Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. Blood (2014) 123(11):1709-19. PMID: 24464016
For over 20 years, my main research work focused on overcoming the resistance of leukaemia and lymphoma cells to chemo- or immuno-therapy, and the roles of mitochondria and BCL-2 family proteins in apoptotic cell death.
Our studies now focus on the impact of the inflammatory microenvironment on survival and treatment resistance mechanisms of chronic lymphocytic leukaemia (CLL) and B cell lymphoma.
Current research focuses are:
BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia Smith LD, Minton AR, Blunt MD et al. Leukemia (2020) 34(7) 640-644
Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20 Guan XW, Wang HQ, Ban WW et al. Cell Death and Disease (2020) 11(7)
Increased autocrine interleukin-6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia Wang HQ, Jia L, Li YT et al. Journal of Cellular Physiology (2019) 234(7) 13994-14006
Blockade of HMGB1 signaling pathway by ethyl pyruvate inhibits tumor growth in diffuse large B-cell lymphoma. Zhang T, Guan X-W, Gribben JG et al. Cell Death Dis (2019) 10(2) 330
Lower expression of Bax predicts poor clinical outcome in patients with glioma after curative resection and radiotherapy/chemotherapy Wang PG, Li YT, Pan Y et al. Journal of Neuro-Oncology (2019) 141(7) 71-81
Correction: Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma (Oncotarget (2015) 6 (2250–2262) DOI: 10.18632/oncotarget.2948) Zhao T, Ren H, Jia L et al. Oncotarget (2019) 10(7) 5569-5570
HIF-2-dependent expression of stem cell factor promotes metastasis in hepatocellular carcinoma Wang X, Dong J, Jia L et al. Cancer Letters (2017) 393(7) 113-124
STAT3 and NF-κB cooperatively control in vitro spontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia Liu F-T, Jia L, Wang P et al. Oncotarget (2016) (1)
CD126 and targeted therapy with tocilizumab in chronic lymphocytic leukemia Liu FT, Jia L, Wang P et al. Clinical Cancer Research (2016) 22(7) 2462-2469
Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outcomes Wang X, Ren H, Zhao T et al. Oncotarget (2016) 7(7) 13717-13729For additional publications, please click here
Ms Arantxa Romero Toledo
Education and Qualifications